Skip to main content

Publications

featured publications

  • Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.

    Current medical research and opinion

    Authors: Johannes Oldenburg, Songkai Yan, Geraldine Maro, Girishanthy Krishnarajah, Andreas Tiede

  • Treatment of the antiphospholipid syndrome with direct oral anticoagulantsPosition statement of German societies.

    VASA. Zeitschrift fur Gefasskrankheiten

    Authors: Rupert Bauersachs, Florian Langer, Christoph Kalka, Stavros Konstantinides, Robert Klamroth, Johannes Oldenburg, Sebastian Schellong, Ute Scholz, Markus Stücker, Edelgard Lindhoff-Last

  • Structure functional insights into calcium binding during the activation of coagulation factor XIII A.

    Scientific reports

    Authors: Sneha Singh, Johannes Dodt, Peter Volkers, Emma Hethershaw, Helen Philippou, Vytautus Ivaskevicius, Diana Imhof, Johannes Oldenburg, Arijit Biswas

  • Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers.

    Circulation research

    Authors: Heiko Rühl, Christina Berens, Franziska I Winterhagen, Sara Reda, Jens Müller, Johannes Oldenburg, Bernd Pötzsch

  • Exploring the structural similarity yet functional distinction between coagulation factor XIII-B and complement factor H sushi domains.

    Journal of thrombosis and thrombolysis

    Authors: Mohammad Suhail Akhter, Sneha Singh, Hamideh Yadegari, Vytautas Ivaskevicius, Johannes Oldenburg, Arijit Biswas

  • Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.

    Therapeutic advances in hematology

    Authors: Toshko Lissitchkov, Anna Klukowska, John Pasi, Craig M Kessler, Robert Klamroth, Raina J Liesner, Larisa Belyanskaya, Olaf Walter, Sigurd Knaub, Johann Bichler, Martina Jansen, Johannes Oldenburg

  • Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.

    Thrombosis and haemostasis

    Authors: Jens Müller, Isabell Pekrul, Bernd Pötzsch, Beate Berning, Johannes Oldenburg, Michael Spannagl

  • Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

    PloS one

    Authors: Delphine Bachelet, Thilo Albert, Cyprien Mbogning, Signe Hässler, Yuan Zhang, Stephan Schultze-Strasser, Yohann Repessé, Julie Rayes, Anna Pavlova, Behnaz Pezeshkpoor, Kerstin Liphardt, Julie E Davidson, Agnès Hincelin-Méry, Pierre Dönnes, Sébastien Lacroix-Desmazes, Christoph Königs, Johannes Oldenburg, Philippe Broët

  • Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder.

    International journal of molecular sciences

    Authors: Sneha Singh, Mohammad Suhail Akhter, Johannes Dodt, Peter Volkers, Andreas Reuter, Christoph Reinhart, Christoph Krettler, Johannes Oldenburg, Arijit Biswas

  • Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.

    BMJ open

    Authors: Johannes Oldenburg, Charles R M Hay, Víctor Jiménez-Yuste, Flora Peyvandi, Jean-François Schved, Johan Szamosi, Bent Winding, Stefan Lethagen